GSK’s Duvroq gets Japanese approval for anaemia caused by CKD

This article was originally published here

Duvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is yet to be approved for any indication anywhere else in the world with the exception of Japan.

The post GSK’s Duvroq gets Japanese approval for anaemia caused by CKD appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply